Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TMPRSS4 | Q9NRS4 | 6/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | POLQ | O75417 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16913918 | 0.87 | TMPRSS4 (0.46) | GSK3BRAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL12132735 | 0.85 | ALDH1A1 (0.61) | GSK3BRAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL14645459 | 0.84 | AR (0.50) | GSK3BRAB9AMAPTFLT1FLT4 | |
| SCHEMBL29879873 | 0.84 | AR (0.50) | GSK3BRAB9AMAPTFLT1FLT4 | |
| SCHEMBL26020575 | 0.83 | RAB9A (0.47) | RAB9ACYP1A2CYP2D6CYP2C19TP53 | |
| SCHEMBL2097720 | 0.81 | CES2 (0.66) | GSK3BCYP2C19MAPTKDM4EPTPN1 | |
| SCHEMBL7786308 | 0.81 | PTPN1 (0.47) | GSK3BPTPN1CES2MRGPRX4P2RX7 | |
| SCHEMBL7787360 | 0.81 | GSK3B (0.44) | GSK3BCYP1A2CYP2C19PTPN1CES2 | |
| SCHEMBL8491232 | 0.81 | RAB9A (0.48) | RAB9ACYP1A2CYP2D6CYP2C19TP53 | |
| SCHEMBL28462798 | 0.80 | RAB9A (0.50) | RAB9ACYP1A2CYP2D6CYP2C19TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288315-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-11-24 | — | — | US | claimed |
| EP-2325178-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-05-25 | — | — | EP | claimed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2015138689-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015109109-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015109109-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| US-20110288315-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2325178-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-05-25 | — | — | EP | disclosed |
| EP-2325178-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010013510-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | ダイソー株式会社 (JP) | 2010-02-04 | — | — | WO | disclosed |
| EP-0735142-B1 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICALS CO LTD (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0080071-B1 | 2-IMIDAZOLYLMETHYL-2-PHENYL-1,3-DIOXOLANES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | BAYER AG (DE) | 1987-05-13 | — | — | EP | disclosed |
| EP-0080071-A2 | 2-Imidazolylmethyl-2-phenyl-1,3-dioxolanes, process for their preparation and their use as fungicides | BAYER AG (DE) | 1983-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288315-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | CYP51A1, KMO, TALDO1 | GSK3B 776/4885RAB9A 3393/4885CYP1A2 42/4885 |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | SMN1; SMN2, FUS, SYNCRIP | GSK3B 3967/4885RAB9A 2507/4885CYP1A2 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.